For healthcare professionals only
GPnotebook

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​
The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.

Prescribing information for United Kingdom and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Focus on: Elderly and frail people with type 2 diabetes

DID YOU KNOW?

Frailty assessment should be a routine component of a diabetes review for all older adults, with glycaemic targets and therapeutic choices modified accordingly.1

Diabetes treatment goals should be individualised in this population, including de-escalation of treatments that have an adverse side-effect profile.1

5-step guide
to adopting an individualised approach
in the management of T2D in the elderly and frail

1. Individualise glycaemic targets

Tighter glycaemic control may cause more harm than benefit in the elderly and frail1

2. Assess and monitor frailty regularly

Use tools like the Rockwood Clinical Frailty Scale to monitor frailty to assist with individualising treatment goals1

3. Simplify treatment regimens

Prioritise simpler regimens with lower risk of hypoglycaemia and consider deprescribing medications that no longer offer benefit or may pose risks to the elderly and frail1

4. Account for comorbidities and functional status

Be aware of the impact of comorbidities on HbA1c1 and be considerate of renal function, cognitive status and nutritional status2

5. Engage in shared decision-making

Use a patient-centric approach and involve patients in decision-making as early as possible to focus on quality of life versus strict clinical targets3

  • VIDEO (Short)
  • 17 min

Click here to view video

Management of type 2 diabetes in the elderly and frail

Hosted by Dr Sarah Jarvis

  • The ideal glycaemic targets for the elderly and frail population with type 2 diabetes
  • How to simplify the management of type 2 diabetes in the elderly and frail population
  • The practicalities of treatment with DPP-4 (dipeptidyl peptidase-4) inhibitors, in particular linagliptin
  • Learning module

Click here to access the learning module

Type 2 diabetes in a frail older person

References:

  1. Strain WD, et al. Diabetes Ther. 2021;12:1227–47.
  2. Bahat G et al. Drugs Aging. 2023;40(9):751–761.
  3. Davies M, et al. Diabetes Care. 2022;45(11):2573–2786.
  • Webinar

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

VIEW HERE
  • VIRTUAL WEBINARS

Initiated and funded by Boehringer Ingelheim

PC-GB-110175 | July 2024

Prescribing information for United Kingdom and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-109826 V3 | August 2025

PC-GB-109918 V3 | August 2025

Trajenta® (linagliptin) prescribing information: UK and ROI.

JARDIANCE® (empagliflozin) prescribing information: UK and ROI.

This website is for healthcare professionals in the United Kingdom and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in the United Kingdom or the Republic of Ireland by clicking below.

I am
I am not

You are leaving https://resources.gpnotebook.com

https://resources.gpnotebook.com is not responsible for content hosted on third party websites.

You will be directed to: https://link.springer.com/article/10.1007/s13300-021-01035-9

Continue
close
Prescribing information for the United Kingdom and the Republic of Ireland 

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel